Cardiovascular Disease and Mortality in Black Women Carrying the Amyloidogenic V122I Transthyretin Gene Variant.
Cardiovascular Disease and Mortality in Black Women Carrying the Amyloidogenic V122I Transthyretin Gene Variant.
复制标题
携带淀粉样变性 V122I 运甲状腺素蛋白基因变体的黑人女性的心血管疾病和死亡率。
DOI:
10.1016/j.jchf.2023.02.003
复制
发表时间:
2023
期刊:
影响因子:
--
通讯作者:
Wassertheil-Smoller,Sylvia
中科院分区:
文献类型:
--
作者:
Haring,Bernhard;Hunt,RebeccaP;Shadyab,AladdinH;Eaton,Charles;Kaplan,Robert;Martin,LisaWarsinger;Panjrath,Gurusher;Kuller,LewisH;Assimes,Themistocles;Kooperberg,Charles;Wassertheil-Smoller,Sylvia
BackgroundLong-term data on cardiovascular disease (CVD) and mortality in female carriers of the transthyretin (TTR) V122I (pV142I) variant, one of the most common variants of hereditary transthyretin cardiac amyloidosis, are sparse and the effects of blood pressure, heart rate, body mass index, and physical activity on CVD outcomes remain largely unknown.ObjectivesThe aim was to first examine the relationship ofTTRV122I (pV142I) carrier status with CVD and mortality and second to investigate the effects of blood pressure, heart rate, body mass index, and physical activity in a large cohort of postmenopausal women.MethodsThe study population consisted of 9,862 non-Hispanic Black/African American women, 9,529 noncarriers and 333TTRV122I carriers, enrolled in the Women’s Health Initiative at 40 centers in the United States. Women were generally healthy and postmenopausal at the time of enrollment (1993-1998). CVD was defined as a composite endpoint consisting of coronary heart disease, stroke, acute heart failure or CVD death, and all-cause mortality. CVD cases were based on self-reported annual mailed health updates. All information was centrally adjudicated by trained physicians. HRs and 95% CIs were obtained from adjusted Cox proportional hazards models.ResultsAmong 9,862 Black female participants (mean age: 62 years [IQR: 56-67 years]), the population frequency of theTTRV122I variant was 3.4% (333 variant carriers and 9,529 noncarriers). During a mean follow-up of 16.1 years (IQR: 9.7-22.2 years), incident CVD occurred in 2,229 noncarriers and 96 carriers, whereas 2,689 noncarriers and 108 carriers died. In adjusted models including demographic, lifestyle, and medical history covariates,TTRV122I carriers were at higher risk of the composite endpoint CVD (HR: 1.52; 95% CI: 1.22-1.88), acute heart failure (HR: 2.21; 95% CI: 1.53-3.18), coronary heart disease (HR: 1.80; 95% CI: 1.30-2.47), CVD death (HR: 1.70; 95% CI: 1.26-2.30), and all-cause mortality (HR: 1.28; 95% CI: 1.04-1.56). The authors found a significant interaction by age but not by blood pressure, heart rate, body mass index, or physical activity.ConclusionsBlack femaleTTRV122I (pV142I) carriers have a higher CVD and all-cause mortality risk compared to noncarriers. In case of clinical suspicion of amyloidosis, they should be screened forTTRV122I (pV142I) carrier status to ensure early treatment onset.
影响因子:
5.3
作者:
A. Laughon;R. Driscoll;N. Wills;R. Gesteland
通讯作者:
R. Gesteland
DOI:
10.1016/0307-4412(85)90224-9
发表时间:
1985
期刊:
Biochemical Education
影响因子:
--
作者:
G. Blair
通讯作者:
G. Blair